Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer

Fig. 4

Genomic alterations and clinical response to SHR-1701 in combination with bevacizumab and XELOX. a Summary of the distribution of SNVs among the SHR-1701 cohorts. b Mutational spectrum of the SHR-1701 genome in the BEP cohort. Substitutions are plotted in different colors, with their context arranged as indicated. c–e Boxplot comparisons of Single Base Substitutions (SBS2, SBS10b, SBS15) between patients achieving a PR and those with SD. f Boxplot comparison of TMB between the PR and SD groups. g Somatic mutational landscape of the SHR-1701 cohort. Each gene (row) and its corresponding alterations in each tumor sample (column) are represented as a heatmap based on the color legend provided below. Samples are arranged according to the number of clinical annotations, which are displayed in the bottom panel. Clinical parameters for each patient are shown beneath the heatmap, while alteration frequencies are illustrated in the right panel. The total number of alterations in each sample is summarized in the upper panel. SNV, single nucleotide variant; BEP, biomarker-evaluable population; SBS, Single Base Substitution; PR, partial response; SD, stable disease; TMB, tumor mutation burden

Back to article page